MK-677 (Ibutamoren) Capsules: What 2026 Research Shows About Oral GH Secretagogue Activity

MK-677 — known in research chemistry as ibutamoren or by the research designation MK-0677 — is one of the most mislabeled compounds in the research peptide space. It is not actually a peptide. It is a non-peptide small molecule, specifically a ghrelin receptor agonist developed originally by Merck in the 1990s. But because it is sold alongside peptides, acts on a receptor that also responds to peptide hormones (ghrelin itself is a peptide), and generates growth hormone downstream effects similar to those of peptide GH secretagogues, it has been functionally adopted into the peptide research catalog industry.

That small molecule status is actually what makes MK-677 interesting. Unlike almost every peptide-class compound — which degrades rapidly in gastric conditions and requires injection or nasal delivery for meaningful systemic bioavailability — MK-677 is genuinely orally active, with substantial published pharmacokinetic data demonstrating capsule-form delivery works. This article covers what the 2026 research literature shows about MK-677, why capsule format is the research-standard presentation, and what researchers should look for when sourcing ibutamoren for laboratory study.

What MK-677 actually is

MK-677 is a non-peptide ghrelin receptor agonist. It binds the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by endogenous ghrelin — and triggers downstream increases in pulsatile growth hormone (GH) and insulin-like growth factor 1 (IGF-1) release.

Chemically, it is a spiroindane derivative, with the formal IUPAC designation N-[1(R)-[(1,2-dihydro-1-methanesulfonylspiro[3H-indole-3,4′-piperidin]-1′-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methylpropanamide methanesulfonate. The CAS number for the mesylate salt is 159634-47-6.

The molecule’s small-molecule structure — molecular weight around 528 Da for the free base — is what allows it to survive oral administration intact. Peptide-based GH secretagogues, by contrast, are generally much larger, degrade in the GI tract, and require parenteral or transmucosal delivery.

Why MK-677 is orally active

Three structural features combine to make MK-677 unusually suited for oral delivery:

1. Small molecular size — at ~528 Da, it is well within the Lipinski “rule of five” molecular weight threshold for oral bioavailability. 2. Lack of peptide bonds — without the amide linkages that digestive enzymes target, MK-677 is not vulnerable to the proteolytic degradation that destroys most peptide drugs in the GI tract. 3. Favorable logP and polar surface area — MK-677 crosses intestinal epithelium efficiently, with published bioavailability in the 60-70% range in animal models.

Published pharmacokinetic studies consistently show that orally administered MK-677 reaches peak plasma concentrations within 60-90 minutes, with a half-life in the 4-6 hour range that supports once-daily dosing in research protocols.

What the research shows about MK-677 activity

The 2010s generated a substantial body of published MK-677 research, which has continued to expand in the 2020s as interest in growth hormone axis modulation for longevity and sarcopenia research grew. Key findings from the published literature:

• Sustained GH and IGF-1 elevation: Published studies have consistently shown that MK-677 produces sustained elevation of both GH pulsatility and IGF-1 steady-state levels in animal and human subject research.
• Lean mass outcomes in older subjects: A notable published trial in older adults documented statistically significant increases in fat-free mass over a 2-month administration period.
• Sleep architecture effects: Research has documented increases in slow-wave sleep phases, consistent with expected GH axis modulation.
• Appetite and caloric intake: As expected from a ghrelin receptor agonist, published studies consistently report increased caloric intake, which is a primary endpoint in some research programs and a confound in others.
• Insulin sensitivity: Published work has shown decreases in insulin sensitivity at sustained dosing, which is a known limitation and a key research variable.

For laboratory research programs investigating GH-axis pharmacology, muscle mass and body composition outcomes, or longevity model work, MK-677 has become a standard research tool precisely because of its oral bioavailability and well-characterized pharmacokinetic profile.

Why capsule format is the research standard

MK-677 is sold in two primary formats in the research peptide supply market:

1. Oral capsules (the standard presentation) 2. Oral liquid solutions (less common but used by some suppliers)

Capsules dominate the market for several reasons:

• Dose precision: a pre-measured 10mg or 12.5mg capsule eliminates the measurement variance that is common with liquid preparations, particularly for research programs running multiple dose arms.
• Chemical stability: MK-677 in dry capsule form is more stable over shelf life than dissolved in liquid vehicle.
• Handling simplicity: capsules are straightforward to store and administer in research protocols without requiring additional solvents or measurement equipment.
• Published literature consistency: the majority of published MK-677 research has used oral capsule or tablet presentations, making capsules the appropriate default for protocol replication work.

Prax’s MK-677 12.5mg × 60 capsules is formulated to match the research-standard dosing range used in the published pharmacokinetic and clinical research literature.

Sourcing standards — what matters for MK-677

Because MK-677 is a small molecule rather than a peptide, the analytical verification standards are slightly different from what researchers should look for with peptide compounds:

• HPLC purity ≥99%, with chromatogram available per batch
• Mass spectrometry identity confirmation (target MW ~528 Da free base, higher for the mesylate salt)
• Independent third-party COA, particularly important for MK-677 because the compound has been the target of counterfeit and under-dosed supply in the research chemical market
• Clear batch numbering linking the product to the COA
• Specification of the salt form — mesylate is the research-standard salt; other forms exist but are less commonly used

In February 2026, published third-party testing surveys documented substantial purity variance across the MK-677 supply market, with several lower-tier suppliers shown to be shipping product at 70-85% purity while labeled as 99%+. This is a vendor quality problem, not a molecule problem — genuine MK-677 at research-grade purity is a well-characterized compound.

Frequently asked questions

Is MK-677 a peptide? No. MK-677 is a non-peptide small molecule (specifically, a spiroindane derivative). It is categorized and sold alongside research peptides because it acts on the ghrelin receptor — the same receptor that responds to the peptide hormone ghrelin — and produces GH-axis effects similar to those of peptide GH secretagogues.

Is MK-677 FDA-approved? No. MK-677 is not FDA-approved for human or veterinary use. It is sold strictly as a research chemical for in-vitro laboratory investigation.

Why is ibutamoren orally active when most peptides aren’t? Because MK-677 is a small molecule, not a peptide. It lacks the amide peptide bonds that digestive enzymes target, and its small molecular weight and favorable physicochemical properties allow it to cross the intestinal epithelium efficiently.

What is the difference between MK-677 and ipamorelin? Both act on the ghrelin receptor system. MK-677 is a non-peptide small molecule that is orally active. Ipamorelin is a pentapeptide that is not orally bioavailable and is typically administered by injection in research protocols. Their selectivity profiles, half-lives, and handling characteristics differ substantially.

What capsule strength is research-standard? The published research literature has used a range of doses, but 10mg and 12.5mg once-daily dosing ranges are most common. Prax’s capsule presentation is formulated at 12.5mg per capsule to align with this research range.

How should MK-677 capsules be stored? Refrigerated storage in the original container is recommended. Shelf life specifications are listed on the batch-specific Certificate of Analysis.

The bottom line

MK-677 is unusual among research “peptide” compounds in that it is not actually a peptide at all — and that structural fact is exactly why oral capsule delivery works for it when it fails for most peptide-class compounds. For researchers investigating GH-axis pharmacology, sarcopenia and body composition research, sleep architecture modulation, or longevity-oriented ghrelin receptor work, MK-677 capsules offer a well-characterized, orally bioavailable tool with a substantial published research base.

As with every research compound, the variable that matters most is supplier quality. In a post-Peptide-Sciences research supply market where purity variance has grown across the industry, independently verified ≥99% HPLC purity and a transparent third-party COA are the minimum acceptable standards.

Our peptide calculator assists with dosing planning across injectable Prax research peptides, and our growth-hormone research peptide collection includes ipamorelin, CJC-1295, and the ipamorelin/CJC-1295 combination for researchers comparing peptide and non-peptide GH secretagogue approaches.

All Prax Peptides products are intended for laboratory research use only. They are not drugs, supplements, or food products, and are not for human or veterinary consumption.